Dionex Monoclonal Antibody Characterization brochure

Worldwide sales of monoclonal antibodies (MAbs) continue to grow rapidly, with many market analysts predicting sales of over US$50bn per year by 2014, due to their extensive use as biotherapeutic drugs in the treatment of human diseases. With this high demand for newer and better MAb candidates, overcoming the characterisation bottleneck becomes vital.

Dionex is able to provide high-throughput, automated solutions to resolve the challenges for MAb characterisation processes, described in a new brochure, Monoclonal Antibody Characterization.

The company’s MAb characterisation platform, built on the UltiMate 3000 HPLC system, is claimed to boost productivity by automating the many manual steps required in the screening and analysis of MAbs and accelerates product development by increasing sample throughput. Fast MAb characterisation and peptide mapping can be accomplished using the Dionex UHPLC+ focused systems.

The capillary ICS-5000 ion chromatography system is suitable for biopharmaceutical carbohydrate analysis. Also included in the platform solution is a wide selection of industry-standard columns for MAbs charge, hydrophobicity and size characterisation as well as the Chromeleon chromatography data system software that not only controls systems but also reports results and provides method validation.